Search the Newsreel

Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?

BrightView Holdings Independent Director Acquires 37% More Stock

BrightView Holdings, Inc. (NYSE:BV) saw its Independent Director, William Cornog, purchase US$562k worth of shares at an average price of US$11.25, increasing his holding by 37%. This purchase comes despite significant insider selling over the past year by the CFO at a higher price. …

AbbVie Stock After the Apogee Financing: What $10 Billion in Notes Signals.

AbbVie recently issued $10 billion in senior notes to finance its $10.9 billion acquisition of Apogee Therapeutics, with the deal expected to close on August 18. Despite narrowing full-year guidance due to acquisition-related dilution, AbbVie reported strong Q2 earnings driven by Skyrizi and Rinvoq …

AbbVie to Acquire Apogee Therapeutics for $10.9 Billion; Apogee Reports Positive Phase 2 Zumilokibart Data and Q2 2026 Results

AbbVie plans to acquire Apogee Therapeutics for $10.9 billion, or $135.11 per share, to bolster its immunology portfolio. This acquisition follows Apogee's positive Phase 2 results for zumilokibart in atopic dermatitis and a $1.3 billion financing deal with Blackstone Life Sciences. The deal is …

Apogee's Atopic Dermatitis Drug Shows 65.9% EASI-75

Apogee Therapeutics announced its Q2 2026 financial results and significant corporate updates, including AbbVie's agreement to acquire the company for approximately $10.9 billion. The acquisition, valued at $135.11 per share in cash, is expected to close in Q3 2026. Additionally, Apogee reported positive Phase …

AbbVie Inc. (ABBV) Stock Analysis: Evaluating Growth Potential With A 11.51% Upside

AbbVie Inc. (ABBV) is a biopharmaceutical company with a strong market presence, a current stock price of $246.04, and a potential upside of 11.51% according to analyst ratings. While the company boasts significant revenue growth, strong operational efficiency, and an attractive dividend yield, its …

Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Analysts have given Pharvaris N.V. (NASDAQ:PHVS) a "Moderate Buy" consensus recommendation, with an average 12-month price target of $50.08, exceeding its current share price of $34.91. While insider selling has occurred recently, the clinical-stage biotech company, focused on hereditary angioedema with its lead candidate …

AbbVie Inc. (NYSE:ABBV) Receives Average Recommendation of "Moderate Buy" from Brokerages

AbbVie Inc. (NYSE:ABBV) has received a "Moderate Buy" consensus rating from 24 brokerages, with an average 12-month price target of $275.70, exceeding its current share price. The company surpassed quarterly earnings expectations with adjusted EPS of $3.65 and revenue of $16.99 billion, marking a …

BrightView’s Q2 Earnings Call: Our Top 5 Analyst Questions

Banco Bbva Argentina SA (BBAR) Earnings Forecast: Future EPS & Revenue Growth Estimates

ABVC Biopharma Inc (ABVC) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for ABVC Biopharma Inc (ABVC), focusing on future EPS and revenue growth estimates. It includes current stock information, market capitalization, and a peer comparison from the biotechnology and medical research sector. The forecast sections cover expected EPS, revenue, …

Can Pharvaris (PHVS) Turn AAE-C1INH Patient Insights Into a Lasting Clinical Advantage?

Pharvaris (PHVS) recently published a study detailing the disease burden of acquired C1 inhibitor deficiency (AAE-C1INH) and validating patient-reported outcome tools. This research directly influenced endpoint selection for their Phase 3 CREAATE trial, potentially strengthening future clinical benefit assessments. While this offers a supporting …

The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call

The 5 Most Interesting Analyst Questions From AbbVie's Q2 Earnings Call AbbVie's second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales growth to strong execution in core immunology therapies, especially SKYRIZI and RINVOQ, and notable …

BV Financial, Inc. Financial Statements – NASDAQ:BVFL

BV Financial, Inc. (NASDAQ: BVFL) is a bank holding company founded in 1873 and headquartered in Baltimore, MD. The company specializes in attracting deposits and originating various types of real estate and consumer loans. Financial data, including market capitalization, revenue, and net income, are …

BrightView Holdings (BV) As Earnings And Guidance Reset The Case For A Pricey Valuation

Behavioral Patterns of BVFL and Institutional Flows

This article analyzes the behavioral patterns and institutional flows of Bv Financial Inc. (NASDAQ: BVFL), indicating a near-term strong sentiment that could lead to a mid-term neutrality and long-term positive bias. It highlights an exceptional 20.7:1 risk-reward setup targeting a 5.9% gain versus 0.3% …

(BV) Movement as an Input in Quant Signal Sets

This article analyzes Brightview Holdings Inc. (NYSE: BV) using AI models to generate trading strategies. It highlights weak near and mid-term sentiment, a neutral long-term outlook, and an exceptional risk-reward setup targeting a 12.7% gain. The analysis provides specific entry, target, and stop-loss points …

Lazard Asset Management LLC Has $192,000 Stock Position in BrightView Holdings, Inc. $BV

Lazard Asset Management LLC significantly reduced its stake in BrightView Holdings, Inc. (NYSE:BV) by 89.9% in the first quarter, now holding 16,292 shares valued at $192,000. Despite institutional investors owning 92.41% of the company, BrightView missed analyst estimates for both EPS and revenue in …

ATAI|ATAI Life Sciences NV|Price:7.250|Chg%:+0.070

AbbVie Inc (ABBV) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

ATAI Life Sciences NV (ATAI) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for ATAI Life Sciences NV (ATAI), detailing its current earnings forecast score, average price target, and analyst ratings. Based on 15 analysts, the average target price is $12.00, suggesting a potential upside of 48.79%. The stock currently holds …

Noticias de acciones de Banco Bbva Argentina SA (BBAR)

Is BrightView Holdings (BV) Fairly Valued As Earnings And Guidance Reset Expectations?

AtaiBeckley (ATAI) Gains On Earnings Revisions, Is The Premium Valuation Justified?

Análise e Previsão das Ações da AbbVie Inc (ABBV)

New Century Logistics (BVI) Ltd (NCEW) Stock News Today

This article provides an overview of New Century Logistics (BVI) Ltd (NCEW) stock news, earnings, analyst ratings, and key developments. It notes that more news will be coming soon and includes current stock performance metrics such as market capitalization and P/E TTM. The page …

BV Financial (NASDAQ:BVFL) Stock Rating Upgraded by Wall Street Zen

BV Financial (NASDAQ:BVFL) has received upgraded stock ratings from Wall Street Zen and Weiss Ratings, moving from "sell" to "hold" and "hold (c+)" to "buy (b-)" respectively. The company's shares are trading near their 12-month high, and MarketBeat data indicates an average analyst rating …

DBV Technologies SA (DBV.HM) options chain

This article provides the options chain information for DBV Technologies SA (DBV.HM) on Yahoo Finance. It displays a summary of the stock's performance, showing its closing price and percentage change. The options chain section indicates that there are currently no calls or puts available …

BV Financial Inc (BVFL) Stock News Today

This article provides the latest stock news for BV Financial Inc (BVFL), showing its current stock price, market capitalization, and P/E ratio. It indicates that more news will be coming soon. The page also includes general information about investment products and a risk warning.

Banco Bbva Argentina SA (BBAR) Stock News Today

This article provides a brief update on Banco Bbva Argentina SA (BBAR) stock news, indicating that more news will be available soon. It includes current stock performance data, market capitalization, and P/E TTM. The content primarily serves as a placeholder for future news and …

Banco BBVA Argentina Secures BCRA Approval for New Director Appointment

Banco BBVA Argentina (BBAR) has received approval from the Central Bank of the Argentine Republic (BCRA) for the appointment of María Soledad Duro Ruiz to its board of directors. This regulatory clearance confirms her eligibility following shareholder designation and a review of her background, …

St. Louis Financial Planners Asset Management LLC Takes $5.01 Million Position in AbbVie Inc. $ABBV

St. Louis Financial Planners Asset Management LLC has acquired a new position in AbbVie Inc., purchasing 19,202 shares valued at approximately $5.01 million, making AbbVie its seventh-largest holding. This comes as AbbVie reported strong Q2 earnings, exceeding revenue and EPS expectations, though its adjusted …

DBV Technologies SA (DBV.HM) stock price, news, quote and history

This article provides detailed financial information for DBV Technologies SA (DBV.HM), including its current stock price, historical data, performance metrics, and key financial highlights. It shows the stock trading at 2.3280 EUR with a 2.28% increase at market close, alongside comparisons to the CAC …

AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed

In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie …

Brightview Holdings Inc (BV) Stock News Today

This page provides current stock news for Brightview Holdings Inc (BV). It shows the stock's market cap, P/E TTM, and recent price changes. The article indicates that more news will be coming soon, and users can track earnings and analyst ratings for BV.

ProQR Therapeutics NV (PRQR) Stock News Today

This article provides current stock information for ProQR Therapeutics NV (PRQR), including its recent trading performance, market capitalization, and links to financial data and analyst ratings. It notes that more news is expected soon for the company. The stock closed at $1.875, down 1.32%.